Healio

Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Medscape

FDA OKs Subcutaneous Vedolizumab for Crohn's Maintenance Therapy

The US Food and Drug Administration (FDA) has approved the subcutaneous administration of vedolizumab (Entyvio) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD ...
Monthly Prescribing Reference

Entyvio Injection Approved for UC, Crohn’s Disease

ENTYVIO (vedolizumab) injection The FDA announced the approval of Entyvio (vedolizumab; Takeda) injection for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to ...
Healthline

Does Medicare Cover Entyvio

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...
FiercePharma

In 2nd attempt, Takeda scores FDA nod for subcutaneous version of Entyvio

Nearly four years after the FDA rejected Takeda’s attempt to develop a subcutaneous formulation of blockbuster Entyvio (vedolizumab), the Japanese company has won the regulator over with its ...